Pharmaron Holdings Limited has announced the acquisition of Bridge Laboratories China, a leading provider of GLP-compliant toxicology services to pharmaceutical and biotech companies around the world.
Bridge Laboratories China is the first CRO in China with western GLP-compliant preclinical toxicology service capabilities and the only preclinical CRO laboratory in China whose data have been accepted by both the FDA and EMEA as part of successful regulatory filings.
Pharmaron Chairman and CEO Dr Boliang Lou said Pharmaron is now the first CRO in China to provide fully integrated drug discovery and development services, from discovery chemistry to IND filings.
“Pharmaron has built an exceptional team of scientists specialised in the areas of discovery and process chemistry, biology, DMPK, pharmacology and GMP manufacturing,” Dr Lou said.
The acquisition includes 84,000sqft facilities and one of the largest and most sophisticated animal vivariums in China that is both AAALAC multi-species accredited and US GLP-compliant.